Jrake_JH
参与了投票
11月,华尔街的主要指数在经历了三个月的疲软后反弹。美国通货膨胀的缓解表明,居高不下的物价正在放松他们对经济的控制。低于预期的消费者物价指数也增强了市场对美联储将很快结束加息周期的信心。这些事态发展表明,美国经济有可能软着陆...
已翻译
![Moo社区聚焦:软着陆是否有助于推动股市增长?](https://ussnsimg.moomoo.com/77777000/editor_image/d1c650d9896832fa983ec82acd1cc87d.png/thumb)
![Moo社区聚焦:软着陆是否有助于推动股市增长?](https://ussnsimg.moomoo.com/77777000/editor_image/3f952d6651ad3cdabb46dc06dd148cbc.jpg/thumb)
![Moo社区聚焦:软着陆是否有助于推动股市增长?](https://ussnsimg.moomoo.com/77777000/editor_image/16381783cf7a3fab9f836c4cbf061786.png/thumb)
+5
134
19
Jrake_JH
参与了投票
在农历新年期间,向亲朋好友致以新年问候是全世界华人的传统。从我观察到的情况来看, 那些发送最衷心的新年问候的人通常会收到最红的红包。
同意与否?
伙计,是时候提高技能了!选择以下一些新春问候,马上给你的亲戚留下深刻的印象!
最后,我们为大家准备了一个小幸运红包...
同意与否?
伙计,是时候提高技能了!选择以下一些新春问候,马上给你的亲戚留下深刻的印象!
最后,我们为大家准备了一个小幸运红包...
已翻译
113
121
Jrake_JH
赞了
German biotech firm Evotec plans to list on the Nasdaq under the symbol "EVO" on November 4th.
The company would look to raise up to $575.5 million in the IPO by offering 22 million American depositary shares (ADSs) at $26.16 each, according to its filing. Each ADS represents one-half of an ordinary share.
According to Reuters, Evotec SE would seek a valuation of about $9.2 billion in its initial public offering in the United States. BofA Securities and Morgan Stanley are the lead underwriters for the offering.
As of October 31st, The company has a market capitalization of $8.2 billion on the Frankfurt Stock Exchange, where its shares are already listed.
Business Overview
Founded in 1993, Hamburg-headquartered Evotec is an industry-leading drug discovery and development partner for the pharmaceutical and biotechnology industry.
It offers a suite of technologies that enable faster and cheaper drug discoveries by pharmaceutical companies.
The company last year received a grant from the Bill & Melinda Gates Foundation to help identify and develop potential monoclonal antibody drugs for the prevention of severe COVID-19.
Evotec's work to date has resulted in 11 disclosed pipeline assets in clinical development, and over 100 pipeline assets in the discovery and preclinical phase.
In the meanwhile, it has developed a broad multi-disciplinary network of collaborations with over 800 partnerships across the pharmaceutical and biotechnology industry and academia.
Evotec generate revenue through three core collaboration routes:
1)“Fee-for-service”: byproviding stand-alone or fully integrated drug discovery and development solutions to partners on a fee-for-service and FTE-rate basis;
2)EVOroyalty: by receiving milestones and royalties on assets;
3)EVOequity: through equity ownership in emerging, highly innovative companies and translational academic institutional projects.
As of June 30, 2021, it had 24 investments with 90 active projects in our EVOequity pipeline.
Financial Performance
Revenues from contracts with customers increased by 17.5%, from €231.0 million for the six months ended June 30, 2020 to €271.3 million in the six months ended June 30, 2021.
The increase is mainly due to a positive performance across all business lines as well as the higher contribution of Just – Evotec Biologics.
Net income increased by €105.5 million from €7.26 million in the six months ended June 30, 2020 to €112.71 million in the six months ended June 30, 2021. The increase is mainly resulted from the fair value adjustment of Evotec’s participation in Exscientia Ltd. in the amount of €116.1 million.
Click to view the prospectus
$Evotec(EVO.US$
The company would look to raise up to $575.5 million in the IPO by offering 22 million American depositary shares (ADSs) at $26.16 each, according to its filing. Each ADS represents one-half of an ordinary share.
According to Reuters, Evotec SE would seek a valuation of about $9.2 billion in its initial public offering in the United States. BofA Securities and Morgan Stanley are the lead underwriters for the offering.
As of October 31st, The company has a market capitalization of $8.2 billion on the Frankfurt Stock Exchange, where its shares are already listed.
Business Overview
Founded in 1993, Hamburg-headquartered Evotec is an industry-leading drug discovery and development partner for the pharmaceutical and biotechnology industry.
It offers a suite of technologies that enable faster and cheaper drug discoveries by pharmaceutical companies.
The company last year received a grant from the Bill & Melinda Gates Foundation to help identify and develop potential monoclonal antibody drugs for the prevention of severe COVID-19.
Evotec's work to date has resulted in 11 disclosed pipeline assets in clinical development, and over 100 pipeline assets in the discovery and preclinical phase.
In the meanwhile, it has developed a broad multi-disciplinary network of collaborations with over 800 partnerships across the pharmaceutical and biotechnology industry and academia.
Evotec generate revenue through three core collaboration routes:
1)“Fee-for-service”: byproviding stand-alone or fully integrated drug discovery and development solutions to partners on a fee-for-service and FTE-rate basis;
2)EVOroyalty: by receiving milestones and royalties on assets;
3)EVOequity: through equity ownership in emerging, highly innovative companies and translational academic institutional projects.
As of June 30, 2021, it had 24 investments with 90 active projects in our EVOequity pipeline.
Financial Performance
Revenues from contracts with customers increased by 17.5%, from €231.0 million for the six months ended June 30, 2020 to €271.3 million in the six months ended June 30, 2021.
The increase is mainly due to a positive performance across all business lines as well as the higher contribution of Just – Evotec Biologics.
Net income increased by €105.5 million from €7.26 million in the six months ended June 30, 2020 to €112.71 million in the six months ended June 30, 2021. The increase is mainly resulted from the fair value adjustment of Evotec’s participation in Exscientia Ltd. in the amount of €116.1 million.
Click to view the prospectus
$Evotec(EVO.US$
![IPO-pedia | German biotech Evotec seeks over $9 bln valuation](https://ussnsimg.moomoo.com/9089963327107909302.png/thumb)
![IPO-pedia | German biotech Evotec seeks over $9 bln valuation](https://ussnsimg.moomoo.com/5952878957367085658.png/thumb)
![IPO-pedia | German biotech Evotec seeks over $9 bln valuation](https://ussnsimg.moomoo.com/811834358451399751.png/thumb)
+2
16
2
Jrake_JH
赞了
专栏 投资理念
投资的核心概念是买股票买入公司。研究公司在行业中的相对优势和竞争力。行业的未来发展前景等。风险较低的投资方法是在世界无法改变的行业中投资垄断性公司。可口可乐、茅台、奢侈品牌爱马仕等,因为未来的现金流折扣很容易预测,而且可以更清楚地看到公司的未来发展。更高的风险是投资能够改变世界的公司,例如颠覆性技术和新能源。科学技术的革命性创新创造了全新的产业,取代了传统产业。你可以参考过去汽油卡车的发明来取代蒸汽机。互联网电子商务的发明影响了传统零售业。当前新能源的进展将在不久的将来影响传统的汽油卡车行业。将来会被完全更换。这种投资方式类似于穆木女士的理念,以及孙正义愿景基金的投资理念。优秀的投资者需要站在首席执行官的肩膀上才能看到公司的未来发展,有时甚至需要更独特的愿景。好公司 + 好行业 + 时间 = 投资成功
$特斯拉(TSLA.US$ $爱马仕(ADR)(HESAY.US$ $可口可乐(KO.US$ $贵州茅台(600519.SH$
$特斯拉(TSLA.US$ $爱马仕(ADR)(HESAY.US$ $可口可乐(KO.US$ $贵州茅台(600519.SH$
已翻译
42
1
Jrake_JH
留下了心情
埃隆·马斯克是世界上最富有的人,他现在的身价与比尔·盖茨和沃伦·巴菲特的总和一样多!太疯狂了!![]()
![]()
他的净资产超过2300亿美元,相当于约87.6万辆法拉利488,或2.5亿部iPhone或625亿台巨无霸!!![]()
![]()
![]()
另外,他想让贝索斯知道自己排名第一。哈哈...![]()
![]()
![]()
马斯克今年的财富增加了超过600亿美元,这要归功于他的强劲表现 $特斯拉(TSLA.US$ 以及SpaceX最近的一次股票出售,该公司的估值为1000亿美元。![]()
![]()
他在管理公司和进行投资方面非常成功。我相信他是最好的企业家和投资者!甚至比尔·盖茨和他的 $微软(MSFT.US$ 还有巴菲特和他的 $伯克希尔-A(BRK.A.US$ 无法比拟!![]()
![]()
![]()
如果你不同意,请告诉我你最喜欢的首席执行官和他的公司!
奖励来电!评论赢取奖励!
我和Moomoo新闻组一起举办活动一个月!我每天都会发布讨论,Moomoo新闻团队将为活动提供奖励积分!我们将在每个工作日选出前 2 个 “喜欢” 和前 3 个 “有见地” 的评论以及每个周末前 10 名 “喜欢” 和前 10 名 “有见地” 的评论作为赢家。
欲了解更多详情,请单击 这里.
关注我加入最新的讨论!
另外,他想让贝索斯知道自己排名第一。哈哈...
马斯克今年的财富增加了超过600亿美元,这要归功于他的强劲表现 $特斯拉(TSLA.US$ 以及SpaceX最近的一次股票出售,该公司的估值为1000亿美元。
他在管理公司和进行投资方面非常成功。我相信他是最好的企业家和投资者!甚至比尔·盖茨和他的 $微软(MSFT.US$ 还有巴菲特和他的 $伯克希尔-A(BRK.A.US$ 无法比拟!
如果你不同意,请告诉我你最喜欢的首席执行官和他的公司!
奖励来电!评论赢取奖励!
我和Moomoo新闻组一起举办活动一个月!我每天都会发布讨论,Moomoo新闻团队将为活动提供奖励积分!我们将在每个工作日选出前 2 个 “喜欢” 和前 3 个 “有见地” 的评论以及每个周末前 10 名 “喜欢” 和前 10 名 “有见地” 的评论作为赢家。
欲了解更多详情,请单击 这里.
关注我加入最新的讨论!
已翻译
![[奖励电话] 埃隆·马斯克是最伟大的首席执行官和投资者!](https://ussnsimg.moomoo.com/4563251728169564083.png/thumb)
![[奖励电话] 埃隆·马斯克是最伟大的首席执行官和投资者!](https://ussnsimg.moomoo.com/5417315979179241507.jpg/thumb)
120
107
Jrake_JH
留下了心情